{"ok":true,"trend":{"id":416929,"platform":"google","region":"GB","key":"retatrutide","title":"retatrutide","url":"https://trends.google.com/trending?geo=GB&q=retatrutide","first_seen":"2026-09-29T23:50:48.233054Z","last_seen":"2026-09-30T04:20:48.135718Z","last_rank":8,"peak_rank":3,"last_volume":500,"peak_volume":500,"seen_count":19,"score":83.53,"category_hint":null,"section":null,"category":null,"summary":"Eli Lilly's experimental drug retatrutide helped people with type 2 diabetes lose around 21% of their body weight in a clinical trial, according to Reuters. The injectable, which targets multiple hormones, is being closely watched as a potential next-generation obesity treatment following the success of tirzepatide and semaglutide.","why":"New trial results for Eli Lilly's obesity and diabetes drug retatrutide were just reported, drawing wide interest as the race for next-generation weight-loss treatments heats up.","tone":"positive","entities":["Eli Lilly","Retatrutide"],"summarized_at":"2026-09-29T23:52:56.242968Z","meta":{"lang":"en","picture":"https://encrypted-tbn3.gstatic.com/images?q=tbn:ANd9GcSrPNt_8_Ac-mU3zIiRrTBIRfP5JflYy-tupix7R3c-d22jrIbztMRWc9eLD-Q","traffic":"500+","published":"Tue, 29 Sep 2026 16:30:00 -0700","picture_source":"The Guardian"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Eli Lilly's retatrutide cuts weight by 21% in diabetes trial","timeline":[{"captured_at":"2026-09-29T23:50:48.233054Z","rank":3,"volume":200},{"captured_at":"2026-09-30T00:05:48.239011Z","rank":4,"volume":200},{"captured_at":"2026-09-30T00:20:46.772399Z","rank":4,"volume":200},{"captured_at":"2026-09-30T00:35:46.489805Z","rank":5,"volume":200},{"captured_at":"2026-09-30T00:50:49.066786Z","rank":6,"volume":200},{"captured_at":"2026-09-30T01:05:45.355989Z","rank":7,"volume":200},{"captured_at":"2026-09-30T01:20:48.596489Z","rank":7,"volume":200},{"captured_at":"2026-09-30T01:35:47.908747Z","rank":7,"volume":200},{"captured_at":"2026-09-30T01:50:47.499708Z","rank":7,"volume":200},{"captured_at":"2026-09-30T02:05:47.190219Z","rank":7,"volume":200},{"captured_at":"2026-09-30T02:20:46.101984Z","rank":7,"volume":200},{"captured_at":"2026-09-30T02:35:47.719826Z","rank":7,"volume":200},{"captured_at":"2026-09-30T02:50:48.101398Z","rank":6,"volume":500},{"captured_at":"2026-09-30T03:05:46.393660Z","rank":6,"volume":500},{"captured_at":"2026-09-30T03:20:48.204125Z","rank":7,"volume":500},{"captured_at":"2026-09-30T03:35:47.713822Z","rank":7,"volume":500},{"captured_at":"2026-09-30T03:50:47.686994Z","rank":7,"volume":500},{"captured_at":"2026-09-30T04:05:47.219042Z","rank":8,"volume":500},{"captured_at":"2026-09-30T04:20:48.135718Z","rank":8,"volume":500}],"posts":[{"platform":"google","url":"https://www.nbcnews.com/health/health-news/retatrutide-type-2-diabetes-lilly-weight-loss-drug-rcna600536","author":"NBC News","title":"People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug","snippet":null,"posted_at":null,"likes":null},{"platform":"google","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-experimental-drug-cuts-weight-by-21-diabetes-trial-2026-09-29/","author":"Reuters","title":"Lilly's experimental drug cuts weight by 21% in diabetes trial","snippet":null,"posted_at":null,"likes":null},{"platform":"google","url":"https://arstechnica.com/health/2026/09/most-powerful-obesity-drug-yet-people-lost-up-to-25-of-weight-in-trial/","author":"Ars Technica","title":"Most powerful obesity drug yet: People lost up to 25% of weight in trial","snippet":null,"posted_at":null,"likes":null}],"elsewhere":[{"id":419585,"platform":"google","region":"BR","title":"retatrutide","last_rank":7,"last_seen":"2026-09-30T02:05:47.190219Z","summary":"Retatrutide, an experimental obesity drug from Eli Lilly, is drawing major attention after trial results showed participants losing up to 25% of their body weight, reportedly making it the most powerful obesity drug tested so far. The findings are fueling discussion about the next generation of weight-loss treatments beyond semaglutide and tirzepatide, with strong interest in the US, UK and Brazil."},{"id":415637,"platform":"google","region":"US","title":"retatrutide","last_rank":10,"last_seen":"2026-09-29T23:50:48.233054Z","summary":"Retatrutide, an experimental obesity drug from Eli Lilly, is drawing attention after trial results showed participants losing up to 25% of their body weight, making it potentially the most powerful obesity drug tested to date. Coverage, including Ars Technica's report on the findings, is fueling discussion about how it might compare to established treatments like tirzepatide and semaglutide."}],"window":"7d"}}